Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 11, 2003Insmed Announces Publication of Investment Profile; Full Text Available on Corporate Website
-
Apr 8, 2003Insmed Chairman to Provide Positive Outlook During CEOcast.com's Virtual Healthcare Conference
-
Apr 8, 2003Insmed Initiates Named Patient Programme For rhIGF-I/rhIGFBP-3, An Investigational Drug for Severe Growth Disorders
-
Apr 7, 2003Insmed Announces Improved Performance Expectations for First Quarter; Lead Product Candidate Prepared to Enter Phase III Trials
-
Apr 4, 2003Insmed Reports Positive Data with rhIGFBP-3 in Cancer; rhIGFBP-3 Improves Effect of Standard Cancer Therapies; rhIGFBP-3 Inhibits Tumor Growth up to 70%
-
Apr 2, 2003Insmed CEO to Highlight Near Term Commercial Opportunity; Lead Drug on Track for Potential FDA Approval in 2004; Cash Expected to Fund Operations Through Potential Approval
-
Apr 1, 2003Insmed Chairman And CEO Provides Positive Outlook in Special Letter to Shareholders
-
Mar 28, 2003Insmed Incorporated Retains Investor Relations International As Investor Relations Counsel; Company to Immediately Implement New Shareholder Communications Program
-
Feb 3, 2003Insmed Incorporated Reports Year-End and Fourth Quarter Financial Results
-
Jan 29, 2003Insmed Reports Positive Effects of SomatoKine -rhIGF-I/rhIGFBP-3- In Adolescent Subjects With Type 1 Diabetes
